
About Curis
Curis is a publicly listed company based in Lexington (United States) founded in 2000. Therapeutics are developed by targeting signaling pathways for multiple cancers. It operates on a Professional Services model. The company has 34 employees. Curis offers products and services including Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Curis, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Curis, Inc. is engaged in the development and commercialization of differentiated therapeutics aimed at improving the lives of cancer patients. The companys efforts are centered on hematologic malignancies and other cancer types. Key programs include Emavusertib for leukemia and lymphoma, Fimepinostat for MYC-altered cancers, and Erivedge for basal cell carcinoma. Research and clinical activities are supported through collaborations and intellectual property licensing with partners like Aurigene and Genentech. The companys pipeline spans preclinical to commercial stages, addressing critical needs in oncology.
- Annual Revenue$9.44 M (USD)-13.43as on Dec 31, 2025
- Net Profit-$7.58 M (USD)82.53as on Dec 31, 2025
- EBITDA-$32.73 M (USD)25.16as on Dec 31, 2025
- Latest Funding Round$45M (USD), Debt – Conventional
Apr 2017
- InvestorsGenentech
& 2 more
- Employee Count34
Products & Services of Curis
Curis offers a comprehensive portfolio of products and services, including Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327.
Developed for treating hematologic malignancies like leukemia and lymphoma.
Targeted for MYC-altered cancers in clinical activity stage.
Approved drug for treating basal cell carcinoma commercially.
Developed for PDL1/VISTA-expressing cancers in clinical stage.
Focused on PDL1/TIM3-expressing cancers at proof stage.
Funding Insights of Curis
- Total Rounds 6
- Last Round Debt – Conventional β $45M
- Investors Count 3
All 6 funding rounds of Curis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $45M | Debt – Conventional | β | β | |
| Mar 2015 | $64.7M | Post-IPO | β | β | β |
| Dec 2012 | $30M | Debt – Venture | β | β | |
| May 2012 | $964,000 | Post-IPO | β | β | β |
| Nov 2010 | $500,000 | Grant | β | β | β |
| Apr 2005 | Post-IPO | β | β |
3 investors in total: 3 institutional.
Investors in Curis
Curis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, HealthCare Royalty Partners and Pharmakon Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Investment management services are provided to the life sciences industry. | pharmakonadvisors.com | New York, United States | ||
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Curis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Curis
19 people are tracked at Curis (9 in leadership, 5 in board & advisors, 5 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Bill Steinkrauss | CFO | Leadership |
James Dentzer | President & CEO | Leadership |
Elizabeth Martinez | Executive Director Of Global Medical Affairs At Curis | Leadership |
Jonathan Zung | Chief Development Officer (cdo) | Leadership |
Kristopher Lake | Senior Director, Business Planning & Analysis | Leadership |
Diantha Duvall | Chief Financial Officer | Leadership |
Rachel Blasbalg (Klein) | Senior Director Human Resources | Leadership |
Frank Waligora | Vp, Technical Operations | Leadership |
Jamison Hoffman Pharmd | Senior Director, Medical Affairs | Leadership |
Martyn D. Greenacre | Chair of the Board | Board & advisors |
Kenneth I. Kaitin | Board Member | Board & advisors |
Lori A. Kunkel | Board Member | Board & advisors |
Marc Rubin | Board Member | Board & advisors |
John Hohneker | Board Member | Board & advisors |
Jennifer Wagner | Sr. Manager, Human Resources | Team |
Sheila Murphy | Assistant Controller | Team |
Rose Cusella | Assistant Controller | Team |
Randolph Noelle | SAB | Team |
Kayli Walker | Accounting Manager | Team |
Complete people profiles for Curis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Curis
Curis is a publicly listed company on the NASDAQ with ticker symbol CRIS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Aug 2000
- Listed onNASDAQ: CRIS
- Listed entityCuris, Inc.
- Exchange sectorHealth technology
- ISINUS2312694084
- Share price$0.61 (-4.41% on the day) · 2026-10-13
- Market capitalisation$1.3M
- EPS (diluted, trailing year)$-14.29
- Volume (last session)213,084
Financials of Curis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.4M | -$7.6M | -$32.7M |
| 2024 | $10.9M | -$43.4M | -$43.7M |
| 2023 | $10.0M | -$47.4M | -$48.1M |
| 2022 | $10.2M | -$56.7M | -$51.6M |
| 2021 | $10.7M | -$45.4M | -$41.1M |
Detailed financial statements for Curis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Curis
4 dated milestones of Curis across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Curis is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Funding Latest funding round, Debt β Conventional, of $45.0M.
Competitors of Curis
Curis has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Curis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Curis
The website of Curis (curis.com) receives about 4.8K visits a month and ranks #3,916,131 among all websites worldwide, #4,962 in Biotechnology and Pharmaceuticals.
- Monthly visits4.8K
▼ 4.4% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,916,131
among all websites
- Category rank#4,962
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.5
- Average visit6 sec
- DevicesDesktop 33% Β· Mobile 67%
Websites whose visitors overlap most with Curis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
investor.seattlegenetics.com | investor.seattlegenetics.com | 100% | β | ||
| ctibiopharma.com | 92% | View details | |||
| xencor.com | 91% | 22.2K | #2,563,685 | View details | |
| optimerpharma.com | 91% | View details | |||
gemacbio.com | gemacbio.com | 91% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 15 similar websites and full traffic analytics for Curis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Curis (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curis
Complete news archive for Curis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curis
Curis was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Curis is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Curis has 34 employees.
Annual revenue of Curis is $9.44M as on Dec 31, 2025.
Curis, Inc. is engaged in the development and commercialization of differentiated therapeutics aimed at improving the lives of cancer patients. The companys efforts are centered on hematologic malignancies and other cancer types. Key programs include Emavusertib for leukemia and lymphoma, Fimepinostat for MYC-altered cancers, and Erivedge for basal cell carcinoma. Research and clinical activities are supported through collaborations and intellectual property licensing with partners like Aurigene and Genentech. The companys pipeline spans preclinical to commercial stages, addressing critical needs in oncology.
Curis offers Emavusertib (CA-4948), Fimepinostat, Erivedge, CA-170, and CA-327.
Yes, Curis is publicly traded on NASDAQ under the ticker symbol CRIS.
Curis has 3 investors. Key investors include Genentech, HealthCare Royalty Partners, and Pharmakon Advisors.
Curis operates through Curis, Inc..
